ORION OYJ |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.27 EUR | 0.00% |
|
-2.21% | -17.83% |
Business Summary
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Number of employees: 3,632
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Generics and Consumer Health
43.5
%
| - | - | 518 | 43.5 % | - |
Branded Products
21.9
%
| - | - | 261 | 21.9 % | - |
Innovative Medicines
19.8
%
| - | - | 235 | 19.8 % | - |
Animal Health
8.7
%
| 99 | 7.4 % | 104 | 8.7 % | +5.06% |
Fermion
6.2
%
| 69 | 5.1 % | 74 | 6.2 % | +7.28% |
Translation Differences and Other Operations
-0.1
%
| 8 | 0.6 % | -2 | -0.1 % | -120.51% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Other Europe
30.8
%
| 399 | 29.7 % | 367 | 30.8 % | -8.03% |
Finland
28.0
%
| 326 | 24.3 % | 334 | 28.0 % | +2.18% |
North America
14.7
%
| 335 | 25.0 % | 175 | 14.7 % | -47.86% |
Other Countries
14.5
%
| 142 | 10.6 % | 173 | 14.5 % | +21.60% |
Scandinavia
12.0
%
| 139 | 10.4 % | 142 | 12.0 % | +2.45% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Director of Finance/CFO | 63 | 00-12-31 | |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
Sinikka Markkula
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Tuukka Hirvonen
IRC | Investor Relations Contact | - | 19-04-30 |
Johanna Ivaska
PRN | Corporate Officer/Principal | - | - |
Paula Rytilä
PRN | Corporate Officer/Principal | - | 06-12-31 |
Julia Macharey
HRO | Human Resources Officer | 47 | Jan. 31 |
Tero Närvänen
PRN | Corporate Officer/Principal | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 | |
| Director/Board Member | 62 | 22-03-22 | |
Eija Ronkainen
BRD | Director/Board Member | 58 | 16-03-21 |
Kari Jussi Aho
BRD | Director/Board Member | 64 | 20-05-05 |
Hilpi Rautelin
BRD | Director/Board Member | 63 | 17-03-21 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 20 | 33,232,361 | 22,811,400 ( 68.64 %) | 0 | 88.90 % |
| Stock B | 1 | 107,901,917 | 102,653,645 ( 95.14 %) | 782,973 ( 0.7256 %) |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
ORION OYJ 0.86% | 932,771 | 0.86% | 34,825,565 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
ORION Pharma GmbH
 ORION Pharma GmbH Pharmaceuticals: MajorHealth Technology Part of Orion Oyj, ORION Pharma GmbH is a German company that develops, manufactures, and markets human and veterinary medicines. The private company is based in Hamburg, Germany. The CEOs are Robert Borgdorf, Satu Maarit Ahomäki, Jari Ilmari Karlson. The company was founded in 1991. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
32.27
EUR
Average target price
39.2
EUR
Spread / Average Target
+21.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.28% | 4.86B | |
| +27.97% | 672B | |
| +23.66% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.30% | 211B | |
| -0.90% | 203B | |
| -10.51% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- ORNBV Stock
- Company Orion Oyj
